Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABSINASDAQ:MXCTNASDAQ:NRCNASDAQ:SLGC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABSIAbsci$3.13-2.8%$3.22$2.01▼$6.33$398.62M2.222.56 million shs1.57 million shsMXCTMaxCyte$2.88+1.4%$3.04$2.21▼$5.26$306.18M1.39533,047 shs289,873 shsNRCNational Research$10.72+0.3%$13.47$9.76▼$35.81$245.98M0.4193,511 shs75,050 shsSLGCStandard BioTools$2.10-4.5%$2.31$1.73▼$3.79$394.95M1.6410.83 million shs33.91 million shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABSIAbsci+0.94%+4.21%+4.89%-19.50%-28.92%MXCTMaxCyte+0.85%+8.81%-8.39%-39.06%-24.06%NRCNational Research+0.56%+1.42%-22.08%-40.48%-68.81%SLGCStandard BioTools0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABSIAbsci1.6055 of 5 stars3.52.00.00.01.20.80.6MXCTMaxCyte2.391 of 5 stars3.52.00.00.02.32.50.6NRCNational Research2.0478 of 5 stars0.03.02.50.03.30.81.3SLGCStandard BioToolsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABSIAbsci 3.00Buy$8.40168.37% UpsideMXCTMaxCyte 3.00Buy$7.50160.42% UpsideNRCNational Research 0.00N/AN/AN/ASLGCStandard BioTools 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest SLGC, ABSI, MXCT, and NRC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/16/2025ABSIAbsciKeyCorpSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$5.00 ➝ $9.004/9/2025ABSIAbsciNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.003/20/2025ABSIAbsciGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.003/19/2025ABSIAbsciHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.00 ➝ $7.003/19/2025ABSIAbsciNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.003/12/2025MXCTMaxCyteBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$6.003/12/2025MXCTMaxCyteStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$11.00 ➝ $9.00(Data available from 4/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABSIAbsci$4.53M87.92N/AN/A$1.90 per share1.65MXCTMaxCyte$38.63M7.93N/AN/A$2.23 per share1.29NRCNational Research$143.06M1.72$0.99 per share10.81$2.02 per share5.31SLGCStandard BioTools$97.67M4.04N/AN/A$3.00 per share0.70Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABSIAbsci-$110.57M-$0.93N/AN/AN/A-2,321.56%-46.56%-39.74%5/13/2025 (Estimated)MXCTMaxCyte-$37.92M-$0.39N/AN/AN/A-78.36%-16.00%-13.93%5/7/2025 (Estimated)NRCNational Research$24.78M$1.0510.21∞N/A17.32%66.52%20.00%5/6/2025 (Estimated)SLGCStandard BioTools-$109.16M-$0.69N/AN/AN/A-159.54%-24.72%-21.62%N/ALatest SLGC, ABSI, MXCT, and NRC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025ABSIAbsci-$0.23N/AN/AN/A$1.07 millionN/A5/7/2025Q1 2025MXCTMaxCyte-$0.10N/AN/AN/A$9.05 millionN/A3/18/2025Q4 2024ABSIAbsci-$0.22-$0.25-$0.03-$0.25$1.77 million$0.67 million1/27/2025Q4 2024NRCNational ResearchN/A$0.28N/A$0.28N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABSIAbsciN/AN/AN/AN/AN/AMXCTMaxCyteN/AN/AN/AN/AN/ANRCNational Research$0.484.48%N/A45.71%N/ASLGCStandard BioToolsN/AN/AN/AN/AN/ALatest SLGC, ABSI, MXCT, and NRC DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date3/24/2025NRCNational Researchquarterly$0.123.27%3/28/20253/28/20254/11/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABSIAbsci0.015.635.63MXCTMaxCyteN/A9.819.22NRCNational Research1.300.470.47SLGCStandard BioToolsN/A17.7917.29Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABSIAbsci52.05%MXCTMaxCyte68.81%NRCNational Research47.26%SLGCStandard BioTools66.35%Insider OwnershipCompanyInsider OwnershipABSIAbsci9.81%MXCTMaxCyte3.00%NRCNational Research2.00%SLGCStandard BioTools14.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABSIAbsci210127.35 million103.59 millionOptionableMXCTMaxCyte80106.31 million102.67 millionOptionableNRCNational Research49022.95 million23.01 millionOptionableSLGCStandard BioTools451188.07 million160.05 millionOptionableSLGC, ABSI, MXCT, and NRC HeadlinesRecent News About These CompaniesStandard BioTools cut to Neutral at KeyBanc on guidanceFebruary 27, 2025 | msn.comStandard BioTools announces publication on study using SomaScan PlatformJanuary 8, 2025 | markets.businessinsider.comStandard BioTools SomaScan Assay Powers Key Insights into Semaglutide Treatment Published in Nature MedicineJanuary 8, 2025 | markets.businessinsider.comThe Standard 100: The top one hundred people shaping London in 2024October 31, 2024 | standard.co.ukStandard BioTools Inc. Reports Q3 2024 Financial PerformanceOctober 31, 2024 | markets.businessinsider.comLAB Unveiled: The Shocking Truth Behind Standard Biotools Inc’s Latest Stock MovementsOctober 22, 2024 | bovnews.comStandard Biotools Inc (LAB) Stock: Analyzing Its Quiet PowerOctober 2, 2024 | bovnews.comWhy Is Standard Biotools Inc (LAB) Stock Lagging Behind -2.21% from Its 50-Day SMA?September 28, 2024 | bovnews.comStandard BioTools Achieves New Record of the Most Protein Measurements on the Most Sample Types with Expansion of the SomaScan® 11K PlatformSeptember 24, 2024 | markets.businessinsider.comStandard Biotools Inc (LAB) Stock: More Resilient Than It AppearsSeptember 10, 2024 | bovnews.comStandard BioTools And 2 Other Penny Stocks Executives Are BuyingAugust 29, 2024 | msn.comStandard BioTools to Present at the Morgan Stanley 22nd Annual Global Healthcare ConferenceAugust 26, 2024 | markets.businessinsider.comStandard BioTools Shares Fall to 52-Week Low After Company Cuts GuidanceAugust 2, 2024 | marketwatch.comStandard BioTools CFO Jeffrey Black ResignsJuly 31, 2024 | marketwatch.comThe latest Standard BioTools Inc (LAB) Stock Technical BulletinJuly 22, 2024 | bovnews.comStandard BioTools Inc (NASDAQ:LAB) stock is trading -18.35 percent below its 52-week highMay 21, 2024 | bovnews.comStandard BioTools Inc. (NASDAQ:LAB) Q1 2024 Earnings Call TranscriptMay 13, 2024 | msn.comStandard BioTools Inc (LAB) Stock: Values And Value IntersectionMay 13, 2024 | bovnews.comStandard BioTools Inc LABApril 18, 2024 | morningstar.comLAB May 2024 2.500 callFebruary 25, 2024 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSLGC, ABSI, MXCT, and NRC Company DescriptionsAbsci NASDAQ:ABSI$3.13 -0.09 (-2.80%) Closing price 04:00 PM EasternExtended Trading$3.14 +0.00 (+0.16%) As of 07:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit. The company was founded in 2011 and is headquartered in Vancouver, Washington.MaxCyte NASDAQ:MXCT$2.88 +0.04 (+1.41%) Closing price 04:00 PM EasternExtended Trading$2.88 0.00 (0.00%) As of 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.National Research NASDAQ:NRC$10.72 +0.03 (+0.28%) Closing price 04:00 PM EasternExtended Trading$10.72 0.00 (0.00%) As of 04:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.National Research Corporation provides analytics and insights that facilitate measurement and enhancement of the patient and employee experience. Its portfolio of subscription-based solutions provides actionable information and analysis to healthcare organizations across a range of mission-critical, constituent-related elements, including patient experience, service recovery, care transitions, employee engagement, reputation management, and brand loyalty. The company also offers marketing solutions that allow the tracking of awareness, perception, and consistency of healthcare brands; assessment of competitive differentiators; and enhanced segmentation tools to evaluate needs, wants, and behaviors of communities through real-time competitive assessments and enhanced segmentation tools. In addition, it provides experience solutions, such as patient experience, employee engagement, health risk assessments, care transition, and improvement tools. Further, the company provides reputation solutions that allow healthcare organizations to share a picture of their organization and ensure that timely and relevant content informs consumer decision-making; and governance solutions for not-for-profit hospital and health system boards of directors, executives, and physician leadership. National Research Corporation was founded in 1981 and is headquartered in Lincoln, Nebraska.Standard BioTools NASDAQ:SLGCSomaLogic, Inc. operates as a protein biomarker discovery and clinical diagnostics company in the United States. It develops slow off-rate modified aptamers (SOMAmers), which are modified nucleic acid-based protein binding reagents that are specific for its cognate protein; and offers proprietary SomaScan services, which provide multiplex protein detection and quantification of protein levels in complex biological samples. The company's SOMAmers/SomaScan technology enables researchers to analyze various biological samples for protein biomarker signatures, which are utilized in drug discovery and development. Its SomaScan's biomarker discoveries use in diagnostic applications for various diseases, including cardiovascular and metabolic disease, nonalcoholic steatohepatitis, wellness, and others. The company also provides SomaSignal, a laboratory-developed test. It serves pharmaceutical and biotechnology companies, and academic and government research institutions. The company has a collaboration agreement with Illumina Cambridge, Ltd for the development of co-branded NGS-based proteomic distributable kits. The company was founded in 1999 and is headquartered in Boulder, Colorado. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy 3 Stocks To Watch For When Tariffs Subside 3 Boring Stocks Outperforming the Market This Year Short Sellers Gave Up on These 3 Names Recently Market Anticipation Builds: Joby Stock Climbs Ahead of Earnings Is Intuitive Surgical a Buy After Volatile Reaction to Earnings? Now Is the Time to Buy ServiceNow—The Rebound Is Real Archer Aviation Gets Analyst Target Upgrade: Time to Load Up? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
